Greer Completes Enrollment for Phase III Trial in Allergy Treatment
Greer has finished enrolling patients for its Phase III clinical trial studying sublingual-oral immunotherapy as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen.
In 31 clinical sites across the country, 430 patients will be treated in this randomized, double-blind, placebo-controlled trial. Patients will be dosed daily with the immunotherapy until mid-October when the short ragweed pollen season has ended.
It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens in the U.S., according to the company.